The researchers found that blinded investigator-rated healing was better for the tripeptide/hexapeptide system, with the difference reaching statistical significance at day 7.
Among patients with eczema, most moisturizers showed some benefit but better results were seen when used with topical active treatment, according to a Cochrane Review.
Climbazole enhances retinoid-associated biological activities in vivo and in vitro, according to a study published online January 19 in the International Journal of Cosmetic Science.
Tridesilon (desonide) Cream, 0.05%, has been made available by Encore Dermatology. This low-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
A subgroup of patients with dermatitis who discontinue topical corticosteroids (TC) after long-term treatment have clinical rebounding triad manifestations.
An antihypertensive was found to reduce side effects from corticosteroid-based creams used for certain skin diseases, reports a study published in the Journal of Investigative Dermatology.
Aqua Pharmaceuticals announced the launch of Cordran Ointment (flurandrenolide) 0.05% for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Perrigo announced it has received final approval for its abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, the generic version of Medicis' Vanos Cream.
Perrigo has received approval from the FDA for Fluocinolone Acetonide Scalp Oil, 0.01% and Fluocinolone Acetonide Topical Oil 0.01%, the generic equivalents to Derma-Smoothe/FS Scalp and Body Oil, respectively.
Taro Pharmaceuticals has received FDA approval for its New Drug Application for Topicort Topical Spray, a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years and older.
Perrigo announced it has begun commercial shipments of Betamethasone Valerate Foam 0.12%, the generic version of Stiefel Laboratories' Luxiq Foam.
Perrigo announced that its partner, Cobrek Pharmaceuticals, received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Betamethasone Valerate Foam 0.12%, the generic version Stiefel Laboratories' Luxiq Foam.
Patients with localized scleroderma (morphea) often experience delay in diagnosis and variability in treatment that is based more on the specialty of the provider than disease characteristics.
Topical corticosteroids offer a more potent anti-inflammatory effect for the treatment of atopic dermatitis (AD), but they may impair the restoration of the skin barrier and can induce skin atrophy, making topical calcineurin inhibitors more suitable for long-term treatment of the disease.
Perrigo Company announced that it received tentative approval of its Abbreviated New Drug Application (ANDA) for clobetasol propionate emulsion foam, 0.05%.